HUTCHMED Sells Major Stake to Focus on Core Business

HUTCHMED (China) Limited (HK:0013) has released an update.

HUTCHMED (China) Limited is divesting 45% of its stake in Shanghai Hutchison Pharmaceuticals Limited, generating approximately $608 million, to optimize its capital structure and focus on its core cancer and immunotherapy businesses. This strategic move allows HUTCHMED to enhance its cash flow and reduce liabilities while retaining a 5% interest in the joint venture. Investors should note that the completion of this transaction is contingent on the satisfaction of various conditions.

For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.